• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    LeMaitre Q1 2018 Sales $26.0mm (+8%), EPS $0.19 (+17%)

    Gabrielle Lakusta
    Apr. 26, 2018 08:54AM PST
    Medical Device Investing

    LeMaitre Vascular (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2018 results, provided guidance, and announced a $0.07/share dividend. As quoted in the press release: Q1 2018 sales of $26.0mm increased 8% (+3% organic) vs. Q1 2017.  Allografts, patches and valvulotomes led growth.  Sales in the Americas and Europe/Middle East/Africa were up …

    LeMaitre Vascular (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2018 results, provided guidance, and announced a $0.07/share dividend.

    As quoted in the press release:

    Q1 2018 sales of $26.0mm increased 8% (+3% organic) vs. Q1 2017.  Allografts, patches and valvulotomes led growth.  Sales in the Americas and Europe/Middle East/Africa were up 6% and 15% respectively, while sales in Asia/Pac Rim decreased 11%.

    Gross margin decreased to 71.1% in Q1 2018 from 71.9% in Q1 2017, primarily due to product mix and manufacturing inefficiencies.

    Operating expenses in Q1 2018 were $13.6mm, a 3% increase vs. the year-earlier quarter. The Company ended the quarter with 94 sales reps vs. 95 at the end of Q1 2017.

    George W. LeMaitre, Chairman and CEO said, “We continue to pursue 10% annual reported sales growth and 20% annual operating income growth.”

    Click here to read the full press release.

    lemaitre vascularmedical device investingeurope
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

    Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×